Ekman P, Snochowski M, Zetterberg A, Högberg B, Gustafsson J A
Cancer. 1979 Oct;44(4):1173-81. doi: 10.1002/1097-0142(197910)44:4<1173::aid-cncr2820440402>3.0.co;2-c.
Biopsy material from primary prostatic carcinoma from 25 patients was analyzed with regard to cytosol content of methyltrienolone (a synthetic androgen) binding sites and the receptor content has been correlated to the clinical response to endocrine therapy. A dextran-coated charcoal technique was used and binding data were calculated from Scatchard plots. In 20 of the tumors detectable levels of methyltrienolone receptor were noted. One of the receptor-positive patients died during radiation therapy before onset of hormonal treatment, and a second patient, who had a highly differentiated carcinoma, so far has not received any endocrine therapy. Of the remaining 18 patients 15 responded well to castration, treatment with estrogens, or Estracyt (approximately 80%). The biopsies from two of the three receptor-positive non-responders contained the lowest measurable receptor levels. Five specimens lacked detectable amounts of methyltrienolone receptor. Four of these patients did not respond to therapy (approximately 80%), but one was "false" negative. Our data indicate that steroid receptor analysis may become an important tool in predicting the value of endocrine therapy in human prostatic carcinoma.
对25例原发性前列腺癌患者的活检材料进行了分析，以研究甲基三烯醇酮（一种合成雄激素）结合位点的胞浆含量，并将受体含量与内分泌治疗的临床反应相关联。采用葡聚糖包被活性炭技术，并根据Scatchard图计算结合数据。在20例肿瘤中检测到了甲基三烯醇酮受体的可检测水平。其中一名受体阳性患者在激素治疗开始前的放射治疗期间死亡，另一名患有高分化癌的患者迄今为止尚未接受任何内分泌治疗。在其余18例患者中，15例对去势、雌激素治疗或癌腺治（Estracyt）反应良好（约80%）。三名受体阳性无反应者中的两名患者的活检标本含有可测量的最低受体水平。五个标本未检测到甲基三烯醇酮受体。这些患者中有四名对治疗无反应（约80%），但有一名为“假”阴性。我们的数据表明，类固醇受体分析可能成为预测内分泌治疗对人类前列腺癌价值的重要工具。
